Acute ischemic stroke
Drug research and approvals for acute ischemic stroke: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 339 studies of acute ischemic stroke are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, and FDA has 0 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 339
- Trials authorized in Canada: 12
- FDA orphan approvals: 0
- EU medicines: 0
- Improving Endovascular Treatment Through Process RefinementsNCT07948694 · Not applicable · Beijing Tiantan Hospital · starts Apr 15, 2026
- Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling DeficitsNCT07944261 · Phase 3 · Shandong Provincial Hospital · starts Oct 15, 2026
- MRS Imaging Evaluation for Acute Minor StrokeNCT07945158 · Not reported · Shanghai Jiao Tong University Affiliated Sixth People's Hospital · starts Aug 3, 2024
- Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation StrokeNCT07933692 · Phase 4 · Shandong Provincial Hospital · starts Oct 1, 2021
- Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler (TCD) for the Occurrence of…NCT07932080 · Not applicable · CHC Montlegia · starts Dec 1, 2026
- Integrated PET/MR Assessment of Brain Recovery After Recanalization of Non-Acute Atherosclerotic MCA OcclusionNCT07927569 · Not reported · Qianfoshan Hospital · starts Mar 21, 2024
- ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time WindowNCT07922317 · Not reported · 115 People's Hospital · starts Jul 6, 2026
- Short-Term External Trigeminal Nerve Stimulation for Acute Ischemic StrokeNCT07911605 · Not applicable · Xidian University · starts Nov 3, 2026
- Sevoflurane vs. Propofol for General Anesthesia in Patients With Acute Ischemic Stroke Treated With Endovascular TherapyNCT07902791 · Phase 3 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · starts Jun 22, 2026
How its trials ended
2,189 ClinicalTrials.gov studies of ischemic stroke in general, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 388 whose ending is known, 37% met their primary endpoint, 12% missed it and 51% stopped early.
- Ongoing72733%
- Completed, result not reported67831%
- Status unknown39618%
- Met its primary endpoint1426%
- Stopped: other or unclear1095%
- Missed its primary endpoint472%
- Stopped: enrollment or feasibility432%
- Stopped: lack of efficacy191%
- Stopped: sponsor or business decision141%
- Stopped: funding9<1%
- Stopped: safety5<1%
| Sep 25, 2026 | A phase 2a multicenter, randomized, double-blind, placebo-controlled, parallel-arm domain within the act-global trial platform, to evaluate the dose-response,…NTS-521 | Neurotrauma Sciences, LLC | Ongoing |
| Jul 10, 2026 | Safety and efficacy of intravenous thrombolysis in patients with ischemic stroke on treatment with direct oral anticoagulants: do-it – the doac intravenous…Tnkase / Activase | Insel Gruppe AG, Inselspital (University Hospital) Bern | Pending |
| Jan 24, 2025 | Optimizing reperfusion to improve outcomes and neurologic function (ORION): a multicenter, double-blind, placebo controlled, randomized, parallel-group, phase…JX10 | Corxel Pharmaceuticals, Co, Ltd | Ongoing |
| Nov 1, 2024 | Phase 2/3 adaptive design, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of DM199 for the treatment of acute ischemic…DM199 (rinvecalinase alfa) | DiaMedica Therapeutics | Ongoing |
| Oct 1, 2024 | A multicenter, double-blinded, placebo-controlled, single ascending dose, twopart, randomized, phase 2 clinical trial to assess safety, tolerability,…BB-031 | Basking Biosciences | Ongoing |
| Aug 15, 2024 | An investigator-initiated phase 3 multicentre open-label blinded-endpoint randomized controlled trial to evaluate the efficacy and safety of very low-dose…Edoxaban | Sunnybrook Research Institute | Pending |
| Dec 5, 2023 | A phase I, open-label, multicenter, pharmacokinetic, pharmacodynamic, and safety study of tenecteplase in adult patients with acute ischemic strokeTnkase | Roche | Pending |
| Dec 10, 2021 | A phase II, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of balovaptan in patients with acute ischemic…Balovaptan (RO5285119) | Roche | Closed |
| Sep 18, 2020 | A multicenter, randomized, double-blinded, placebo-controlled, parallel group, single-dose design to determine the efficacy and safety of nerinetide in…Nerinetide (NA-1) | Nono Inc | Closed |
| Dec 18, 2019 | A randomized, double-blind, placebo-controlled proof-of-concept study to assess the safety and efficacy of elezanumab in acute ischemic strokeElezanumab (ABT-555) | AbbVie | Closed |
| Oct 14, 2024 | GlyburideTreatment of large territory acute ischemic stroke | Remedy Pharmaceuticals, Inc. | Designated |
| Jan 12, 2017 | GlyburideTreatment of severe cerebral edema in patients with acute ischemic stroke | Remedy Pharmaceuticals, Inc. | Designated |
| Apr 11, 2014 | H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Se…Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset | NoNO, Inc. | Designated |
| Apr 18, 2011 | Tissue Plasminogen activatorTreatment of acute ischemic stroke (AIS) in children age 16 years and younger. | Catherine Amlie-Lefond, MD | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA